Acta NaturaeActa NaturaeActa Naturae2075-8251Acta Naturae Ltd1072110.32607/20758251-2010-2-4-105-111ArticlesСтатьиResearch ArticleA Novel Approach to the Development of Anticarcinogenic VaccinesA Novel Approach to the Development of Anticarcinogenic VaccinesGlushkovA NApalkoS Vapalko@ngs.ruFilipenkoM LMatveevaV ABakulinaA YuLuninV GKostyankoM VInstitute of Human Ecology, Siberian Branch, Russian Academy of SciencesInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of SciencesGamaleya Research Institute of Epidemiology and MicrobiologyInstitute of Human Ecology, Siberian Branch, Russian Academy of SciencesKemerovo State University1512201024VOL 2, NO4 (2010)ТОМ 2, №4 (2010)10511117012020Copyright ©; 2010, Glushkov A.N., Apalko S.V., Filipenko M.L., Matveeva V.A., Bakulina A.Y., Lunin V.G., Kostyanko M.V.Copyright ©; 2010, Glushkov A.N., Apalko S.V., Filipenko M.L., Matveeva V.A., Bakulina A.Y., Lunin V.G., Kostyanko M.V.2010Glushkov A.N., Apalko S.V., Filipenko M.L., Matveeva V.A., Bakulina A.Y., Lunin V.G., Kostyanko M.V.Glushkov A.N., Apalko S.V., Filipenko M.L., Matveeva V.A., Bakulina A.Y., Lunin V.G., Kostyanko M.V.https://creativecommons.org/licenses/by/4.0https://actanaturae.ru/2075-8251/article/view/10721

Human exposure to chemical carcinogens is an important etiological factor in cancer diseases. In this article, we will discuss a new approach to the development of anticarcinogenic vaccines. The main task in our research was to select a benzo[a]pyrene immunomimetic peptide considered as a hapten-specific component. For this purpose, we synthesized carcinogen-protein conjugates and prepared mono- and polyclonal antibodies to benzo[a]pyrene. Phage display technology was used to select the benzo[a]pyrene immunomimetic peptide, followed by an evaluation of the immunological properties of the obtained peptide. The obtained benzo[a]pyrene immunomimetic peptide could only simulate chemical carcinogens in the frame of the pIII protein. As a result, we prepared a recombinant protein composed of the benzo[a]pyrene immunomimetic peptide and pIII-encoding sequences. Using ELISA, we demonstrated that the recombinant protein specifically interacts with the anti-benzo[a]pyrene monoclonal antibody (mAB B2). Using molecular modeling, we predicted the 3-D structure of the mAB B2 active center and analyzed the characteristics of its interaction with different polycyclic aromatic hydrocarbons, as well as with the benzo[a]pyrene immunomimetic peptide. Thus, a comprehensive analysis of the results of the obtainment of hapten-specific components of anticarcinogenic vaccines allowed us to outline a strategy for future development in this direction.

benzo[a]pyreneanticarcinogenic vaccineimmunomimetic peptidephage displaymolecular modelingCreech H.J., Oginsky E.L., Tryon M. // Cancer Res. 1947. V 7. P. 301-304.Moolten F.L., Schreiber B., Rizzone A. // Cancer Res. 1981. V. 41. P. 452-459.Chagnaud J.L., Faiderbe S., Geffard M. // Acad.Sci. Paris, Sciences de la vie. 1993. V. 316. P. 1266-1269.Silbart L.K., Rusmussen M.V., Oliver A.R. // Vet. Hum. Toxical. 1997. V. 39 (1). P. 37-43.Kostyanko M.V., Glushkov A.N. Patent № 2141114, RF, 6 G 01 N 33/5, 1998.Muckerheide A., Apple Raimond J., Pesce Amadeo J., Michale Gabriel J. // The Journal of Immunology. 1987. V. 138. P. 833-837.Glushkov A.N., Apalko S.V., Matveeva V.A., Kostyanko M.V., Cherno S.V. // Russian J. Immunology. 2009. V. 3(12). P. 30-38.Kohler G., Milstein C. // Nature. 1975. V. 256. P. 495-497.Glushkov A.N., Kostyanko M.V., Cherno S.V., Vasilchenko I.L. // Russian J. Immunology. 2002. V. 7. P. 41-46.Glushkov A.N., Apal’ko S.V., Filipenko M.L., Matveeva V.A., Khrapov E.A., Kostyanko M.V. // Molecular Genetics, Microbiology and Virology. 2008. V. 23. P. 147-152.Glushkov A. N., Apal’ko S. V., Bakulina A. Yu., Matveeva V. A., Khrapov E. A., Kostyanko M. V., Sil’nikov V. N., Filipenko M. L. // Molecular Biology. 2010. V. 44. P. 699-707.Gomes M., Santella R.M. // Chem. Res. Toxicol. 1990. V. 3. P. 307-310.Scharnweber T., Fisher M., Suchanek M., Knopp D., Niessner R. // Fresenius J Anal Chem. 2001. V. 371. P. 578-585.Yamashita. N. Nishama S. United State Patent № US 6,277,964 B1, 2001.Glushkov A.N., Apalko S.V., Filipenko M.L., Matveeva V.A., Khrapov E.A., Kostyanko M.V. Patent № 2357975, RF, C07K 16/42, A61K 38/04, C12P 21/03, 2009Böttger V., Peters L.-E., Micheel B. // J. Mol. Recognit. 1999. V. 12. P. 191-197.Terpe K. // Appl Microbiol Biotechnol. 2003. V. 60. P. 523-533.